

SAFETY DATA SHEET



Covexin® 10

Page 1 of 5

Section 1: Identification of the Substance and Supplier

Product name	Covexin 10
Recommended use	Clostridial Vaccine for sheep and cattle.
Company details	MSD Animal Health, 33 Whakatiki Street, Upper Hutt Phone: 0800 800 543 Fax: 0800 808 100 Website: www.msd-animal-health.co.nz Hours: 8 am – 5 pm, Mon – Fri
Emergency telephone	0800 764 766 (0800 POISON) 24 hours human health 0800 243 622 (0800 CHEMCALL) 24 hours
Date of preparation	August 2011

Section 2: Hazards Identification

Hazard classifications	6.5B
Priority identifiers	WARNING
Secondary identifier	6.5B May cause an allergic skin reaction
Risk & Safety Phrases	R43 May cause sensitisation by skin contact

Section 3: Composition/Information on Ingredients

Chemical name	CAS number	Concentration
<i>Clostridium perfringens</i> Type A toxoid (inactivated)	N/A	Varies
<i>C. perfringens</i> Type B toxoid (inactivated)	N/A	Varies
<i>C. perfringens</i> Type C toxoid (inactivated)	N/A	Varies
<i>C. perfringens</i> Type D toxoid (inactivated)	N/A	Varies
<i>C. sordellii</i> toxoid (inactivated)	N/A	Varies
<i>C. novyi</i> Type B toxoid (inactivated)	N/A	Varies
<i>C. haemolyticum</i> toxoid (inactivated)	N/A	Varies
<i>C. septicum</i> toxoid (inactivated)	N/A	Varies
<i>C. tetani</i> toxoid (inactivated)	N/A	Varies
<i>C. chauvoei</i> whole cell culture (inactivated)	N/A	Varies
Thiomersal (Preservative)	54-64-8	<1%

Covexin® 10

Section 4: First Aid Measures

Necessary first aid measures

ACCIDENTAL SELF-INJECTION Obtain medical attention - show this SDS. Accidental self injection may lead to an inflammatory response and medical advice should be sought on the management of deep injections, particularly those near a joint or associated with bruising. If possible the application of gentle squeezing pressure with absorbent material (e.g. facial tissues) at the injection site will swab up unabsorbed vaccine. Strong squeezing of the site should be avoided. The damaged area should be thoroughly cleansed and a topical antiseptic applied.

INHALATION Remove to fresh air. If any trouble breathing, get immediate medical attention. Administer artificial respiration if breathing has ceased. If irritation or symptoms occur or persist, consult a doctor.

SKIN CONTACT In case of skin contact, while wearing protective gloves, carefully remove any contaminated clothing, including shoes, and wash skin thoroughly with soap and water. If irritation or symptoms occur or persist, consult a doctor.

EYE CONTACT In case of eye contact, immediately rinse eyes thoroughly with plenty of water. If wearing contact lenses, remove only after initial rinse, and continue rinsing eyes for at least 15 minutes. If irritation occurs or persists, consult a doctor.

INGESTION Rinse mouth and drink a glass of water. Do not induce vomiting unless under the direction of a qualified medical professional or Poison Control Centre. If symptoms persist, consult a doctor.

Required instructions

For advice contact the National Poisons Centre 0800 POISON (0800 764 766) or a doctor.

Notes for medical personnel

Accidental self-injection: Treat symptomatically. Some risk of hypersensitivity from injection. Contains safety tested inactivated bacterial toxins. Contamination of the needle must be considered.

This product is a vaccine for use in animals. Pathogenic clostridia bacterial strains may cause infection to damaged skin. Local irritation to the eyes, skin, or respiratory tract may occur following direct contact or inhalation of the product. As with any vaccine, exposure may cause hypersensitivity reactions.

Section 5: Fire Fighting Measures

Type of hazard	Not classified as flammable
Fire hazard properties	Not applicable
Regulatory requirements	Not applicable
Extinguishing media and methods	Carbon dioxide (CO ₂), extinguishing powder or water spray.
Hazchem code	Not applicable
Recommended protective clothing	Wear full protective clothing and self-contained breathing apparatus (SCBA).

SAFETY DATA SHEET



Covexin® 10

Page 3 of 5

Section 6: Accidental Release Measures

Emergency procedures Wear chemical resistant gloves and overalls, facemask or goggles. Prevent further spillage. Adsorb spilled product and place in sealable container for disposal. Wash down affected area with water plus detergent. Absorb and collect washings and place in the same sealable container for disposal. Seek advice from the local authority regarding disposal.

Section 7: Handling and Storage

Precautions for safe handling Avoid contact with skin, eyes, and mucosa. Keep containers adequately sealed during material transfer, transport, or when not in use. See Section 8 (Exposure Controls) for additional guidance.

Regulatory requirements Emergency Plan required where quantities greater than 1000L are present.

Handling practices Avoid contact with skin. Keep containers adequately sealed during material transfer, transport, or when not in use.

Approved handlers Not required.

Conditions for safe storage Store in original container. Keep out of reach of children.

Store site requirements Store between 2 and 8°C. DO NOT FREEZE.

Packaging PG III (Limited Quantities – Schedule 4)

Section 8: Exposure Control/Personal Protection

Workplace exposure standards No WES have been set for this substance

Application in the workplace Ensure adequate ventilation. Keep container sealed when not in use.

Exposure standards outside the workplace No TEL is set for this substance at this time
EEL - Not applicable

Personal protection Wear chemical resistant gloves, facemask or goggles.

Engineering controls The health hazard risks of handling this material are dependent on many factors, including physical form, duration and frequency of process or task, and effectiveness of engineering controls. Site-specific risk assessments should be conducted to determine the feasibility and the appropriateness of all exposure control measures. Exposure controls for normal operating or routine procedures follow a tiered strategy. Engineering controls are the preferred means of long-term or permanent exposure control. If engineering controls are not feasible, appropriate use of personal protective equipment (PPE) may be considered as alternative control measures. Exposure controls for non-routine operations must be evaluated and addressed as part of the site-specific risk assessment.

SAFETY DATA SHEET

Covexin® 10

Section 9: Physical and Chemical Properties

Appearance	Clear white to off-white liquid
Boiling Point	Not determined
Melting/Softening point	Not applicable
Vapour Pressure	100kPa
Specific Gravity	1.00
Solubility (H ₂ O)	Soluble
Percent Volatiles	Not determined
Evaporation Rate	Not determined

Section 10: Stability and Reactivity

Stability of the substance	Stable under normal conditions.
Conditions to avoid	Avoid high temperatures.
Material to avoid	Avoid food products.
Hazardous decomposition products	Carbon oxides (CO _x)

Section 11: Toxicological Information

Acute effects for individual ingredients only

ORAL	Thiomersal: LD50 40mg/kg/bw (rat) [ERMANZ]
TEL	No TEL is set for this substance at this time.

Chronic/long term effects for individual ingredients only

Thiomersal has been documented as a sensitiser. [All references from NTP]

Section 12: Environmental Information

Effects for individual ingredients only

EEL	Not applicable
-----	----------------

Section 13: Disposal Considerations

Disposal information	Disposal Dispose of unused contents in a suitable landfill. Container Disposal Dispose of empty vaxipak by puncturing and burying in a suitable landfill. Do NOT burn.
Reference	Current version of NZS 8409 Management of Agrichemicals

SAFETY DATA SHEET



Covexin® 10

Page 5 of 5

Section 14: Transport Information

Relevant information Not classified as a dangerous good for transport

Section 15: Regulatory Information

Regulatory status ERMA Approval Code: HSR000015
For full listings of controls see www.epa.govt.nz

ACVM Registration No: A9028
For conditions of registration see www.foodsafety.govt.nz

RESTRICTED VETERINARY MEDICINE

HSNO and ACVM controls **Emergency Plan:** 1000 Litres

Section 16: Other Information

Additional information Covexin is a registered trademark.

Schering-Plough Animal Health Ltd known as MSD Animal Health, is a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, USA. Schering-Plough urges each user or recipient of this SDS to read the entire data sheet to become aware of the potential hazards associated with this material. This SDS summarises, at the date of issue, our best knowledge of the health and safety hazard information. Although reasonable care has been taken in the preparation of this document, Schering-Plough Animal Health Ltd extend no warranties and make no representations as to the accuracy or completeness of the information contained therein, and assume no responsibility regarding the suitability of this information for the user's intended purposes or for the consequence of its use. Each individual should make a determination as to the suitability of the information for their particular purpose(s).